
A Simple Equation Shows The S&P 500 Falling Another 20% Or More
The biggest question or concern is, 'Has the market reached a low or will the sell-off continue?' One way to answer that question is to look at an equation that is used to determine a stock price or Index value:
Earnings x Multiple = Price
Earnings component is exposed downwards
John Butters, Vice President and Senior Earnings Analyst at FactSet, wrote in his weekly analysis on Friday, April 4, that 'during the first quarter, analysts lowered EPS estimates by a larger margin compared to the four most recent averages.' During the quarter March quarter's EPS fell by 4.2% ($62.89 to $60.23) vs. the average of 3.3% for the past 20 quarters.
2025's full-year estimate dropped by 1.6% from $274.12 to $269.67 over the quarter. The projection has fallen from approximately $279 in late August last year.
S&P 500 2025 EPS
John Butters, Vice President and Senior Earnings Analyst, FactSet
Now that President Trump is imposing worldwide tariffs it is widely expected that earnings will fall. While there will be information provided with first quarter earnings announcements, there will still be a lot of unknowns. So here are projections based on percentage declines from $269.67.
Valuation component is at best at equilibrium
The S&P 500's earnings multiple peaked at approximately 22.2x in early November last year. Butters estimates that is has fallen to 19.4x as of last Friday. This is below the five-year average of 19.9x and above the 10-year average of 18.3x. The S&P 500's forward 12-month P/E ratio is now at 18.5x based on Tuesday's close.
S&P 500 forward 12-month P:E ratio
John Butters, Vice President and Senior Earnings Analyst, FactSet
Uncertainty leads to lower valuation multiples and there is a lot of uncertainty in the economy and the markets, driven by President Trumps actions, and not just his tariff policy. The number of Executive Orders that are essentially dismantling Federal Agencies and allowing DOGE to essentially lay off people add more layers to investors' concerns.
Tariff uncertainty isn't going to become clear anytime soon
Unless President Trump announces some concrete and real tariff deals, and not hyperbole, it is hard to see how earnings and valuation both don't fall. My thought is that Trump isn't going to back down. Yes, there will be some wins, at least from an optics perspective, but especially with China neither Trump nor Xi wants to be the first to flinch.
Another tell from the Administration is Vietnam. Vietnam offers zero tariffs and Trump administration says not enough. If the goal of the Trump administration is to get Vietnam to import as much as it exports that isn't going to happen. In 2023 Vietnam's GDP was $430 billion vs. the United States' $27.4 trillion, or 1.5% the size of the United States. And the U.S. doesn't make what Vietnam wants, while Vietnam makes what U.S. consumers wants.
O'Rourke's Tuesday note included, "Today's eye-opener that contributed to the negative equity market reversal was U.S. Trade Representative Jamieson Greer. Greer testified before the Senate Finance Committee regarding the President's Trade Policy Agenda. Greer made many statements that should alarm investors.'
O'Rourke added, "This last exchange may be both the most telling and the most alarming. Senator Mark Warner asked Greer about the 10% tariff the Administration was applying to Australia. Greer responded, 'We're addressing the $1.2 trillion deficit, the largest in human history that President Biden left us with. We should be running up the score in Australia, they ban our beef, and they ban our pork…' At that point Warner cut him off and stated that the U.S. runs a trade surplus with Australia. It is a fairly sizable $17.6 billion surplus. If Australia applied the Administration formula, the U.S. surplus is 52.5% of U.S. exports to Australia, and they would charge us a 26% tariff.'
I've heard many stories about products on boats right now that will be much more expensive when they land and some already have price stickers on them.
Who eats the tariff cost? And if you reprice the products sales will more than likely be lower and margins will take a hit.
Earnings times valuation equals price
Current earnings of $269.97 times Tuesday's valuation of 18.5x equals the S&P 500 Index value of 4,983 at the close.
These are S&P 500 values based on decreased earnings at the current 18.5x valuation.
These are S&P 500 values based on lower valuation at the current earnings of $269.97.
These are calculations on what the S&P 500 could fall to based on decreased earnings and lower valuations.
Markets hate uncertainty, leading to lower prices
It is hard to build a case that earnings will move higher or that investors nerves will get better, which is needed for the markets to rebound. Probably the best-case scenario is the 2% drop in earnings and a small fall in valuation to 18 times earnings leading to only a further 4.7% drop. However, it is more likely that the S&P 500 Index will fall at least another 10% and it could be 20% or more.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
What a weaker dollar means for inflation
The US dollar ( has fallen this year, and that can have big implications for inflation. RSM chief economist Joe Brusuelas talks about that connection and when the impact of tariffs may start to show in the US economy. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime. turning out to the dollar index, it's seen many swings we know amid economic uncertainty. Joe, you highlight what the moves in the currency mean for inflation? Walk us through that. All right. When you get a sustained 10% decline in the value of the dollar, typically, you should expect to see a 1/2 of 1% increase in inflation over the next 6 to 12 months. We clearly are at that point, even though we had a nice rebound. I think it was 3.3% for the month of July, strongest month for the greenback this year, but nevertheless, the policy mix out of the administration, all points towards a weaker dollar, and I think that's what we're going to get. Moreover, when you take a look at import prices, especially import prices ex petroleum, it tells the tale. We're going to see more inflation and a weaker dollar going forward. Does Trump want a strong dollar? I would think he does, and I think, well, I think like all politicians, he wants to have his cake and eat it, too. He doesn't want de-dollarization, clearly, but he wants a weaker dollar because A, it really tends to juice the tech sector, and B, it will provide relief to the beleaguered manufacturing sector that's been in an effective recession for the past couple of years. Is it too soon to say the kind of impact the softer dollars had during this earnings season, particularly what it's meant for the multinationals? It's way too early to jump on that bandwagon. I think we're really going to be talking in the fourth quarter earnings, and then next year. Moreover, a lot of those firms that he wants to help are actually having real problems with the tariff issue because, you know, 45% of everything we import goes into domestic manufacturing. So policies at a cross purposes, a good portion of the time this year, which is why that economy slowed to 1.2% growth in the first half of the year, and we think it's not going to do much better. Our forecast for this year is 1.1%. Can I ask you when we talk about these tariff policies? We've been talking about them all show. There's the near to intermediate impact, but how long do we have to wait to see what the long-term impact is? Meaning, do I have to wait till does it have to be August 2026, and Joe and Josh are back on set for me to really know, okay, it's really boosted manufacturing job. It's really opened up all these new markets for American business. It's really raised this much revenue. It's a little worse, actually. So as of midnight last night, on once we get to October 5th, we're going to have an effective 18.3% tariff. The real problem is we won't really understand what any of this means, not till October 5th, 2026, but more like October 5th, 2027. Why? Why do you say that, Joe? Because it takes so long to pass through the tariff costs. You know, there are four points along the chain. You've got your retail, you've got your consumers, you've got your importers, and you've got your exporters. At each point of the supply chain, you're going to see a bit of it absorbed, a bit of it eaten. When we went through this in 2018, for example, we didn't see the full price of the increase in the price of washing machines, dryers, and dishwashers caused by tariffs show up on consumers' balance sheets until about two years later. Turned out 90% of that cost was eaten entirely by consumers. So when we talk about whether where the cost falls falls on the value chain, and there was this big debate, maybe it's really the key debate inside the Fed. Tell me if I'm wrong, but this debate about whether the the the tariff induced inflation is one time or transitory persistent. Even if it's one time, it could go on for some time. Is that part of the point? Well, that's right, and that's why they've been counseling patients because you just don't know. Right now, for all of the noise, right? The tariff rate that's showing up, which is causing revenues to rise, right? And from the Trump administration's point of view, that's an absolutely good thing. It's about 8.85%. It's not 30, it's not 50, it's not 15. But as we get into mid-October, it'll be closer to 20 is my sense because we're still not done with Mexico, and we're still not done with China, and then USMCA has to be renegotiated next year. So this is going to be a variable target. It's going to be a moving target, but nevertheless, if you cause the average price of goods imported in the United States to rise by 18.3%, that's going to be eaten. And here's why we say that. There's a lot of talk that, well, foreign exporters are just eating the price. You know, they're going to engage in invoice pricing. If that was the case, import prices would be falling significantly. They're not. They're actually rising. So that's just not happening. So that means it's not the exporter, it's going to be the importer, the retail, or the consumer. Those points on the chain where those are going to be eaten. Joe, I can honestly say that given the news flow today, you were the perfect guy to be sitting in that chair. That's very kind of you to say. Thank you. Thank you, sir. Thank you so much, Joe.
Yahoo
23 minutes ago
- Yahoo
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J., August 01, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300,000 restricted shares of the Company's common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Kalbermatten and the Company. The Compensation Committee of the Company's Board of Directors approved the awards as an inducement material to Mr. Kalbermatten's employment in accordance with Nasdaq Listing Rule 5635(c)(4). About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the "Freedom System") currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit View source version on Contacts Investor Contact: Louisa Smithinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
24 minutes ago
- Business Wire
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) ('KORU Medical' or the 'Company'), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300,000 restricted shares of the Company's common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Kalbermatten and the Company. The Compensation Committee of the Company's Board of Directors approved the awards as an inducement material to Mr. Kalbermatten's employment in accordance with Nasdaq Listing Rule 5635(c)(4). About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the 'Freedom System') currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit